ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0742

Effect of IA OnabotulinumtoxinA and Vanilloids on Substance P and Neurokinin 1 Receptor Expression in the Dorsal Root Ganglia of Mice with Monoarthritis

Hollis Krug1, Nicole Blanshan2, Christopher Dorman2 and Sandra Frizelle2, 1Minneapolis VAHCS and University of Minnesota Medical School, Minneapolis, MN, 2Minneapolis VAHCS, Minneapolis

Meeting: ACR Convergence 2020

Keywords: Animal Model, Neuroimaging, pain, Therapy, alternative

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 7, 2020

Title: RA – Animal Models Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Neurotoxins are increasingly being proposed as analgesics for arthritis pain. Phase II and III clinical trials have shown efficacy but with potential toxicities such as rapidly progressive osteoarthritis that may be neurally mediated. We have shown efficacy of intra-articular (IA) onabotulinumtoxinA (BTX) and the vanilloids capsaicin (CAP) and resiniferatoxin (RTX) in monoarthritis in mice. To better understand the effect of these toxins on the sensory nervous system we examined their effect on the expression of substance P (SP) and neurokinin 1 receptor (NK1) in the dorsal root ganglion (DRG).

Methods: C57/Bl6 male mice received intra-articular (IA) Complete Freund’s Adjuvant (CFA) to produce chronic inflammatory monoarthritis. IA therapies were given at appropriate intervals before examination and DRG harvest. Tissue samples were obtained after arthritis induction at 12 weeks of age from mouse dorsal root ganglia (DRG) and were subjected to immunohistochemistry and real-time reverse transcription polymerase chain reaction (RT-PCR). Neurotransmitter substance P (SP) protein expression was measured as percent of  DRG neurons expressing SP. Both SP and receptor neurokinin-1 (NK1) gene expression were quantified using RT-PCR and expressed as a fold change relative to GAPDH values.

Results: CFA induction resulted in a significant increase in % SP protein expressing cells in  DRG’s but gene expression of SP and NK1 were not significantly changed from naïve. Neither vanilloids nor BTX had any effect on SP protein expression in nonarthritic animals. Only low dose RTX significantly increased SP gene expression in nonarthritic animals   but had no effect onNK1 gene expression . High dose RTX, CAP and BTX all normalized % SP protein expressing cells in the DRG of arthritic animals but NK1 and SP gene expression was not significantly different from naïve. Interestingly, SP gene expression was more variable in all treated arthritic animals and in nonarthritic animals treated with BTX and CAP. NK1 gene expression in low dose RTX and CAP treated non arthritic animals was also more variable than in other groups. In general, BTX and CAP produced an increase in SP gene expression in nonarthritic animals but this was not significant.

Conclusion: Alterations in SP protein expression in the DRG of mice with chronic monoarthritis does not appear to be related to increased gene expression of either SP or NK1. Although the mechanism of action of BTX and vanilloids is hypothesized to be quite different, there does not appear to be a consistent effect of impaired neurotransmitter release (BTX) or enhanced release (vanilloids) on SP or NK1 gene expression. Although numbers were small in this experiment, variability may be due to inherent differences in the animals’ pain perception, pain behavior and  response to therapy. Further studies to correlate pain behavior to SP and NK1 expression and to TRPV1 expression would be informative.

Substance P and NK 1 Receptor Gene and Protein Expression in the DRG of Mice with Inflammatory Monoarthritis: Effect of Neurotoxin Treatment.


Disclosure: H. Krug, None; N. Blanshan, None; C. Dorman, None; S. Frizelle, None.

To cite this abstract in AMA style:

Krug H, Blanshan N, Dorman C, Frizelle S. Effect of IA OnabotulinumtoxinA and Vanilloids on Substance P and Neurokinin 1 Receptor Expression in the Dorsal Root Ganglia of Mice with Monoarthritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/effect-of-ia-onabotulinumtoxina-and-vanilloids-on-substance-p-and-neurokinin-1-receptor-expression-in-the-dorsal-root-ganglia-of-mice-with-monoarthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-ia-onabotulinumtoxina-and-vanilloids-on-substance-p-and-neurokinin-1-receptor-expression-in-the-dorsal-root-ganglia-of-mice-with-monoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology